西迈克斯 CX 深 沪
交易中 05-14 11:46:36 美东时间
13.325
+0.075
+0.57%
华盛通- 最 高13.39
- 今 开13.31
- 成交量 257.03万股
- 最 低 13.145
- 昨 收 13.25
- 总市值 192.27亿
- 52周最高 13.67
- 市盈率 静 48.19
- 换手率 0.18%
- 52周最低 6.5628
- 委 比 58.52%
- 总股本 14.43亿
- 历史最高 13.67
- 量 比 1.60
- 振 幅 1.85%
- 历史最低 1.3777
- 每 手 1
- 风险率 2.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股盘后 | eBay Inc.涨12.90%，TPG Inc Class A涨4.83%
eBay Inc.涨12.90%；TPG Inc Class A涨4.83%；游戏驿站涨4.03%
05-02 06:10
Cemex Files 2025 Integrated Report With U.S. Regulators
Cemex SAB ( ($CX) ) just unveiled an update. Cemex, S.A.B. de C.V., the Mexican...
04-27 18:29
美股大行评级 | 潜在涨幅33%！大小摩等9家大行上调英特尔目标价；Popular、都福集团、联合太平洋、联合租赁等获多家大行上调评级
今日重点评级关注：瑞银：维持SS&C科技"买入"评级，目标价从112美元升至115美元；Piper Sandler：维持儒博实业"超配"评级，目标价从530美元升至540美元
04-27 14:04
Cemex Q1 2026 Earnings Call: Complete Transcript
Cemex (NYSE:CX) held its first-quarter earnings conference call on Thursday. Be...
04-24 00:17
Earnings Scheduled For April 23, 2026
Companies Reporting Before The Bell • Popular (NASDAQ:BPOP) is estimated to rep...
04-23 19:11
Cemex Q1 EPS $0.16 Beats $0.11 Estimate, Sales $4.019B Beat $3.768B Estimate.
Cemex (NYSE:CX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.11 by 45.45 percent. This is a 68 percent decrease over earnings of $0.50 per share from the same period last
04-23 18:08
Cemex Q1 Earnings Preview
Cemex (CX) is scheduled to announce Q1 earnings results on Thursday, April 23rd, before market open. The consensus EPS Estimate is $0.11 and the consensus Revenue Estimate is $3.86B More on Cemex CEME...
04-22 22:32
Shares of construction materials and engineering-related companies are trading higher after Iran signaled that the Strait of Hormuz will remain open for the duration of the ceasefire, easing concerns inflation risk and spurring expectations for monetary easing.
Shares of construction materials and engineering-related companies are trading ...
04-18 02:59
美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元
04-13 14:07
